Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
With
Carematix, VAS (Vital Art and Science)
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with CNV secondary to AMD and not other causes in at least one eye identified by the investigator to be eligible for ranibizumab treatment
Patients with a BCVA letter score in the study eye is 24 or better using an ETDRS chart measured at 4 meters distance
You may not be if
Patients with any concurrent ocular condition that may result in visual loss during the study
Patients with past (within the prior 6 months) or current use of, or likely need for, systemic medications that are known to be toxic to the lens, retina, or optic nerve
Clareo Health | A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
